Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plasma frozen within 24 hours (PF24 or FP24) is a blood component prepared from a single unit of whole blood or via apheresis. Unlike Fresh Frozen Plasma (FFP), which must be frozen within 8 hours of collection, PF24 is frozen within 24 hours and stored at -18°C or colder. This product contains all stable coagulation factors, including fibrinogen and prothrombin, though it may contain slightly reduced levels of labile factors like Factor VIII and Factor V compared to FFP. It is clinically utilized for the management of bleeding in patients with acquired multiple coagulation factor deficiencies, such as those resulting from liver disease, massive transfusion, or the reversal of warfarin effects when specific concentrates are unavailable. It is also used in plasma exchange procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on plasma frozen within 24 hours.